Immuneering (IMRX) shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP with 9 months median follow up on Thursday, September 25, 2025. The Company additionally shared plans for two presentations at upcoming scientific conferences. Presentations: Updated Overall Survival Data in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP, with 9 Month Median Follow Up. Encore Presentation of Updated Overall Survival Data in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP at the PanCAN Scientific Summit. Immuneering plans to present a poster titled “Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients” on Sunday September 28 at the Pancreatic Cancer Action Network Scientific Summit 2025 in Boston MA. Review of Preclinical Data on Deep Cyclic Inhibitors. The Company additionally plans to make an oral presentation titled “Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in RAS-Mutant Cancers” on September 17 at the 7th RAS-Targeted Drug Development Summit taking place September 16-18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering files to sell 9.18M shares of Class A common stock for holders
- Immuneering’s Strategic Partnerships and Promising Clinical Developments Justify Buy Rating
- Immuneering announces clinical supply agreement with Eli Lilly
- Immuneering prices 6.3M shares at $3.95 in private placement
- Immuneering Corp. Reports Strong Trial Results and Patent Win